Error loading player: No playable sources found

47616

Keynote Presentation

Date
January 24, 2023
This product is not available for individual purchase, but it is available as part of the following products:



Laura Sepp-Lorenzino, Ph.D. joined Intellia Therapeutics in 2019 as Chief Scientific Officer and is responsible for Research and Early Development. Intellia is harnessing CRISPR-based technologies to revolutionize the future of medicine. Laura previously held leadership positions at Vertex, Alnylam and Merck. She serves in the Board of Directors of Taysha Gene Therapies, the Alliance for Regenerative Medicine and the Oligonucleotide Therapeutics Society, and on the Scientific Advisory Boards for Thermo Fisher Scientific, the U.K. Nucleic Acid Therapies and Arsenal Capital Partners.  She received her professional degree in Biochemistry from the University of Buenos Aires, Argentina, and both her M.S. and Ph.D. in Biochemistry from New York University.

Related Products

Thumbnail for Plenary Session 4 - Resolving Complexity: Innovative Analytical Technologies for Characterization of Complex Modalities
Plenary Session 4 - Resolving Complexity: Innovative Analytical Technologies for Characterization of Complex Modalities
In-depth analytical characterization of biological drugs and vaccines is important to aid in their development, and innovation in analytical technologies is crucial for the advancement of complex modalities…